Sutro Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-106.79	-119.2	-105.54	-32.13	-55.74	-35.32	-19.69	1.7
Depreciation & Amortization	10.44	8.29	9.77	4.3	4.78	4.54	4.99	5.66
Share-Based Compensation	24.91	26.3	23.24	11.92	10.31	2.87	1.39	0.97
Other Operating Activities	-40.18	88.16	-9.16	-51.89	-24.37	40.59	-23.77	-21.49
Operating Cash Flow	-111.62	3.55	-81.68	-67.8	-65.02	12.68	-37.07	-13.15
Capital Expenditures	-4.32	-7.86	-15.32	-7.13	-3.48	-1.56	-3.32	-4.38
Acquisitions	0	0.01	0.01	0.09	0	0.08	0.08	0
Change in Investments	0.39	-27.17	-82	7.64	-47.65	-78.71	35.84	13.97
Investing Cash Flow	-3.92	-35.02	-97.32	0.6	-51.13	-80.19	32.6	9.59
Share Issuance / Repurchase	14.34	58.15	4.24	254.56	1.11	84.57	0.1	0.18
Debt Issued / Paid	123.71	-9.38	0	15	-5	0	15	0
Other Financing Activities	-0.49	-0.46	-0.99	-0.31	-0.3	86.22	-0.46	-0.01
Financing Cash Flow	137.55	48.31	3.26	269.25	-4.18	170.79	14.64	0.18
Net Cash Flow	22.01	16.84	-175.74	202.05	-120.34	103.28	10.17	-3.39
Free Cash Flow	-115.93	-4.31	-97	-74.93	-68.5	11.13	-40.39	-17.53
Free Cash Flow Margin	-75.41%	-6.36%	-156.76%	-175.39%	-160.30%	28.96%	-78.06%	-29.35%
Free Cash Flow Per Share	-1.93	-0.09	-2.10	-2.30	-2.98	1.93	-90.17	-43.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).